Is utilization of health services for HIV patients equal by socioeconomic status? Evidence from the Basque country by García Goñi, Manuel et al.
García-Goñi et al. International Journal for Equity in Health  (2015) 14:110 
DOI 10.1186/s12939-015-0215-6RESEARCH Open AccessIs utilization of health services for HIV
patients equal by socioeconomic status?
Evidence from the Basque country
Manuel García-Goñi1*, Roberto Nuño-Solinís2, Juan F. Orueta3 and Francesco Paolucci4,5Abstract
Introduction: Access to ART and health services is guaranteed under universal coverage to improve life expectancy
and quality of life for HIV patients. However, it remains unknown whether patients of different socioeconomic
background equally use different types of health services.
Methods: We use one-year (2010–2011) data on individual healthcare utilization and expenditures for the total
population (N = 2262698) of the Basque Country. We observe the prevalence of HIV and use OLS regressions to
estimate the impact on health utilization of demographic, socioeconomic characteristics, and health status in such
patients.
Results: HIV prevalence per 1000 individuals is greater the lower the socioeconomic status (0.784 for highest; 2.135
for lowest), for males (1.616) versus females (0.729), and for middle-age groups (26–45 and 46–65). Health
expenditures are 11826€ greater for HIV patients than for others, but with differences by socioeconomic group
derived from a different mix of services utilization (total cost of 13058€ for poorest, 14960€ for richest). Controlling
for health status and demographic variables, poor HIV patients consume more on pharmaceuticals; rich in
specialists and hospital care. Therefore, there is inequity in health services utilization by socioeconomic groups.
Conclusions: Equity in health provision for HIV patients represents a challenge even if access to treatment is
guaranteed. Lack of information in poorer individuals might lead to under-provision while richer individuals might
demand over-provision. We recommend establishing accurate clinical guidelines with the appropriate mix of health
provision by validated need for all socioeconomic groups; promoting educational programs so that patients
demand the appropriate mix of services, and stimulating integrated care for HIV patients with multiple chronic
conditions.
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The Human Immunodeficiency Virus (HIV) is a global
public health issue with more than 36 million affected.
The highest prevalence is found in Sub-Saharan Africa
where nearly 5 % of adults live with HIV, being 69 % of
all people living with HIV in the world [1]. Although
HIV mortality was huge in the 1980s, the development
in the 1990s of highly active antiretroviral therapy
(ART) was determinant to reduce rates of death and* Correspondence: mggoni@ucm.es
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oped countries, with general access to ART, HIV be-
haves as a chronic condition. By 2012, more than half of
the HIV world population is in developing countries
with inequalities in the access to ART and with a huge
rate of mortality [2].
Hence, there are two completely different realities in
health policy and planning when looking at HIV. First,
in developed countries with mostly universal access to
ART, HIV is a chronic condition. There, the challenge in
health systems is to become high-performing chronic
care systems [3] and efficient given the increasing evolu-
tion of health expenditures [4]. That is feasible byrticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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[5] to chronic patients and to whether patients are suf-
fering more than one chronic condition at the same time
[6] in order to adapt their demand to their need. Here, it
remains unknown whether there is equity in the use
of health services by patients of different socioeconomic
background even when access is guaranteed by the health
system. Second, in low and middle-income countries
where the challenge is to increase the access to ART [7].
Worldwide, inequity in access is a crucial challenge deal-
ing with HIV. However, most studies look at inequity from
the second perspective, focusing on increasing inter-
national rates of access to ART where it is needed [8], its
role on prevention [9], on mortality [10], its impact in
different groups of individuals as sex workers [11] or
injecting drug users [12], or early diagnosis in infants [13].
We contribute to the literature by developing a different
analysis looking at the first mentioned reality: HIV health
policy and planning in developed countries where access
to ART is guaranteed.
We look at the Basque Country, a region in Spain,
where access to public healthcare services is universal
and free at the point of use, where ART is free and pa-
tients only pay a copayment rate in other pharmaco-
logical treatments [14]. We utilize individual data from
the entire Basque population (2.26 million inhabitants)
on diagnoses, socioeconomic information and standard-
ized health expenditures. We test whether patients of
different socioeconomic background equally use differ-
ent types of health services.
Data and methods
We utilize the database prepared by the population
stratification program (PREST) of the Basque Country
including the practical totality of its population: every
individual covered on 31 August 2011 by the public
health insurance in the Basque Country and who was
covered for at least 6 months in the previous year, re-
gardless of whether they made any contact with or use
of the Basque Health Service. The analysis refers to one
year, from September 1st, 2010 to August 31st, 2011.
There are 2,262,698 individuals, being 50.90 % female.
As for the age distribution, 15 % are children (younger
than 18) and 20 % are over 65, being the average individ-
ual 43.69 years old. It is therefore important to remark
that it is not a random sample but the real population in
terms of health policy and planning.
Our dataset combines three types of information. First,
diagnoses information is based on hospital discharges,
emergency department, primary care medical records, and
prescriptions. They all are coded according to the ICD-9-
CM [15] (diagnoses) and ATC [16] (pharmaceuticals).
Second, out of utilization we obtain individual standard-
ized health expenditures. Third, we utilize socioeconomicinformation. For the sake of our analysis, we only look at
the HIV diagnosis in order to differentiate among HIV
patients and non-HIV reported individuals. With respect
to health expenditures, the cost of the public health ser-
vices provision is based on use. However, there are no
market prices within the Basque Health Service and costs
are estimated through standardization of total health
expenditures per type of service. We take into account the
number of visits to primary care, specialist care, Accident
& Emergency, rehabilitation sessions, outpatient care,
laboratory tests, radiological examinations, and various
outpatient procedures such as dialysis, radiotherapy and
chemotherapy. Cost of hospitalization and outpatient
surgery is assigned through the cost-weights of the corre-
sponding diagnosis-related groups (DRGs). Finally, the
cost of ART, provided in public hospitals in the Basque
Country, has been calculated as the average cost of all
ART provided in 2012. Total number of patients with
ART was 5002 and total expenditure in ART treatment
was of 38501376€, for an average cost per treatment of
7697€. Finally, the cost of pharmaceutical prescriptions
(excluding ART) recorded in electronic health records is
based on market prices. Information on socioeconomic
status is derived out of the deprivation index (DI), an
ordinal variable elaborated for Spain in 2008 [17] categor-
izing into five socioeconomic groups (SEG) by quintiles.
The DI allows for the estimation of socioeconomic and
environmental inequities among inhabitants by censal
code. It takes into account five dimensions including the
percentages of residents who are manual workers, un-
employed, temporary employees, or have an inadequate
level of educational attainment, overall and also specific-
ally among young people.
We use OLS regressions to identify whether there are
inequities in the use of of health services provision of
any type for HIV patients in a population in which
access to ART and other treatments is free and granted.
Following the risk adjustment literature, our dependent
variable is health expenditures for HIV patients on age
groups, which, as mentioned above, is directly related to
the utilization of health services (standardized health
expenditures by use). With respect to our independent
variables, because we do not observe all variables that
might affect health expenditures we use fixed effect by
socioeconomic groups (SEG). We do the same for the
different types of health expenditures (provision) and for
total health expenditures. In that further estimation
approach, we take into account the individual age and
the number of chronic conditions suffered as the risk
adjustment literature states that greater need of health
provision derives in greater expected health expend-
iture [18]. The aim is to control for healthcare needs,
taking the individual number of comorbidities as a
proxy. In order to construct those variables, we utilize a
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team based on the related literature [19–21]. We cap-
ture the role of multimorbidities by defining three cat-
egories: 1 to 3 comorbidities, 4 to 6, and 7 or more.
The specification for our estimation model is given by:
Health Expendituresi ¼
X
j
αjageij þ
X
k
βkSEGki þ
X
l
δlNMorbli þ εi
Results
Table 1 presents a description of the Basque Country
population and its prevalence of HIV as a function of
the demographic, socioeconomic characteristics, and by
gender and age groups subject to the PREST dataset.
Prevalence for the total population is of 1.164 per 1000
individuals. HIV prevalence is more than double for
males than for females (1.616 vs 0.729) although for
young individuals from 16 to 25, females present a
greater prevalence (0.245 vs 0.192). More than half of all
HIV-reported patients belong to the group of 46 to
65 years old (1361 out of 2635), being also important
the group of those from 26 to 45 (1135 cases). The
remaining age groups also have HIV patients although
prevalence is very small. Interestingly, we observe the
process of ageing in the HIV population with 8 cases of
HIV patients older than 80. Finally, HIV prevalence de-
creases with socioeconomic status (being from richest to
poorest SEG 0.784, 0.819, 1.095, 1.114, and 2.135 re-
spectively), with significant differences between the first
two SEG, the third and fourth, and the poorest SEG that
presents a prevalence three times that of the richest SEG
and almost double that of the total population. Socio-
economic status makes a difference in prevalence for age
groups older than 26, being highest for the poorest SEG
between 46 and 65 years old (prevalence ratio of 4.208).
Provided their health service utilization, the Basque
population presents an average total health expenditures
of 1132€, being of 1118€ for non-HIV (reported) individ-
uals, and of 13260€ for HIV patients. Table 2 shows ex-
penditures by type of health service and for non-HIV and
HIV patients. Hospitalization is the most expensive type
of health service (372€), being the second Primary Care
(261€) and the third specialist care (255€). Differently,
ART (7687€) is the most expensive type of provision for
HIV patients, being second hospitalization (3372€), and
third specialist care (1334€). Although for every type of
provision HIV patients are more expensive than non-HIV
in absolute terms, it is worth to look at relative expendi-
tures. ART represents 58.05 % of total health expenditures
for HIV patients. However, if we take for granted ART and
do not take it into account, relative weight of expenditures
on hospitalization are much more important for HIV pa-
tients (60.62 % vs 33.32 %) and some greater for specialist
care (23.99 % vs 22.87 %) while relative expenditures onA&E (4.83 % vs 3.25 %), primary care (23.33 % vs 6.80 %)
and pharmaceutical prescriptions (15.65 % vs 5.34 %) are
greater for non-HIV patients.
Table 3 presents the average cost for HIV patients by
provider and SEG. The cost on ART, by construction, has
been considered to be identical for all individuals. Primary
care and pharmaceutical prescriptions are more used by
poorer individuals while hospitalization and specialist care
are more used by richest individuals. Precisely, those are
the most expensive types of health provision without tak-
ing ART into account. Consequently, the Basque Country
allocates a greater amount of public health resources in
HIV patients in the richest SEG (14960€) while it allocates
lower resources in HIV patients in the poorest SEG
(13058€), and lowest for the third SEG (12585€). Figure 1
crosses the prevalence ratio and average total health ex-
penditures for the five socioeconomic groups. While
prevalence is negatively related to socioeconomic status
(lower prevalence for richer SEG), total health expendi-
tures for HIV patients is highest for the richest SEG and
the trend of both series seems to be opposite. Figure 2
shows the proportion of HIV patients with different num-
bers of comorbidities by SEG. Even if there are some dif-
ferences, the distribution of chronic conditions is similar
in each SEG and for the total HIV population having
about 76 % of them at least another chronic condition.
Our regression analysis is presented in Table 4. For
every type of health provision we run different age
groups as explanatory variables. We then add to the esti-
mation the independent variables corresponding to the
socioeconomic status and morbidity burden through the
number of chronic conditions. Our main result show
how socioeconomic status is significant for any type of
health provision even controlling for healthcare need
through the number of chronic diseases suffered by pa-
tients. Thus, patients of different SEG seem to utilize
differently health providers: HIV patients in the richest
SEG significantly use more specialist and hospital care
while those in poorest SEG (4th and 5th) utilize slightly
more only on primary care and pharmaceutical prescrip-
tions. Differences in the significant coefficients between
richest and lowest SEG for hospital and specialist care
expenditures are of 2072.9€ (12967.66€–10894.76€) and
388.11€ (2918.92€–2530.81€) while differences between
lowest and richest SEG in primary care and pharmaceut-
ical expenditures are of 21.64€ (990.29€–968.65€) and
31.06€ (962.66€–931.60€). Consequently, our results
support the existence of inequities in the provision of
health services for HIV patients by SEG once controlling
for their health status. This finding is aligned with others
in the literature, with specialist treatment being pro-rich
within the British NHS when looking at several chronic
conditions (others than HIV) [22]. With respect to our
other control variables, age is only important when it is
Table 1 HIV prevalence ratio by socio-demographic groups in the Basque Country
Target population HIV Prevalence
ratio per
1000
population
Prevalence
with
respect to
the
population
average
N % N %
All 2,262,698 100 2635 100 1.165 1.00
Sex groups
Males 1,111,050 49.10 1796 68.16 1.616 1.39
Females 1,151,648 50.90 839 31.84 0.729 0.63
Age groups
Age 0 to 15 305,573 16 0.052 0.04
Males 157,884 51.67 10 62.50 0.063 0.05
Females 147,689 48.33 6 37.50 0.041 0.03
Age 16 to 25 192,636 42 0.218 0.19
Males 98,802 51.29 19 45.24 0.192 0.17
Females 93,834 48.71 23 54.76 0.245 0.21
Age 26 to 45 715,995 1135 1.585 1.36
Males 366,970 51.25 702 61.85 1.913 1.64
Females 349,025 48.75 433 38.15 1.241 1.07
Age 46 to 65 621,406 1361 2.190 1.88
Males 307,222 49.44 1010 74.21 3.288 2.82
Females 314,184 50.56 351 25.79 1.117 0.96
Age 66 to 80 298,687 73 0.244 0.21
Males 135,878 45.49 50 68.49 0.368 0.32
Females 162,809 54.51 23 31.51 0.141 0.12
Age over 80 128,401 8 0.062 0.05
Males 44,294 34.50 5 62.50 0.113 0.10
Females 84,107 65.50 3 37.50 0.036 0.03
Socioeconomic groups
First SEG 479,316 376 0.784 0.67
Males 228,747 47.72 252 67.02 1.102 0.95
Females 250,569 52.28 124 32.98 0.495 0.42
Second SEG 487,140 399 0.819 0.70
Males 238,951 49.05 277 69.42 1.159 1.00
Females 248,189 50.95 122 30.58 0.492 0.42
Third SEG 457,665 501 1.095 0.94
Males 226,345 49.46 353 70.46 1.560 1.34
Females 231,320 50.54 148 29.54 0.640 0.55
Fourth SEG 422,729 471 1.114 0.96
Males 209,966 49.67 309 65.61 1.472 1.26
Females 212,763 50.33 162 34.39 0.761 0.65
Fifth SEG 415,848 888 2.135 1.83
Males 207,041 49.79 605 68.13 2.922 2.51
Females 208,807 50.21 283 31.87 1.355 1.16
All 2E + 06 100 2635 100 1.165 1.00
Socioeconomic groups
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Table 1 HIV prevalence ratio by socio-demographic groups in the Basque Country (Continued)
First SEG 479,316 376 0.784 0.67
Age 0 to 15 67,569 14.10 3 0.80 0.044 0.04
Age 16 to 25 45,043 9.40 1 0.27 0.022 0.02
Age 26 to 45 137,891 28.77 149 39.63 1.081 0.93
Age 46 to 65 140,490 29.31 206 54.79 1.466 1.26
Age 66 to 80 60,085 12.54 16 4.26 0.266 0.23
Age over 80 28,238 5.89 1 0.27 0.035 0.03
Second SEG 487,140 399 0.819 0.70
Age 0 to 15 69,980 14.37 4 1.00 0.057 0.05
Age 16 to 25 42,220 8.67 10 2.51 0.237 0.20
Age 26 to 45 152,153 31.23 160 40.10 1.052 0.90
Age 46 to 65 135,980 27.91 205 51.38 1.508 1.29
Age 66 to 80 60,097 12.34 18 4.51 0.300 0.26
Age over 80 26,710 5.48 2 0.50 0.075 0.06
Third SEG 457,665 501 1.095 0.94
Age 0 to 15 65,088 14.22 3 0.60 0.046 0.04
Age 16 to 25 37,706 8.24 10 2.00 0.265 0.23
Age 26 to 45 146,271 31.96 210 41.92 1.436 1.23
Age 46 to 65 125,084 27.33 269 53.69 2.151 1.85
Age 66 to 80 58,785 12.84 9 1.80 0.153 0.13
Age over 80 24,731 5.40 0 0.00 0.000 0.00
Fourth SEG 422,729 471 1.114 0.96
Age 0 to 15 47,674 11.28 3 0.64 0.063 0.05
Age 16 to 25 34,220 8.10 11 2.34 0.321 0.28
Age 26 to 45 138,400 32.74 205 43.52 1.481 1.27
Age 46 to 65 115,524 27.33 242 51.38 2.095 1.80
Age 66 to 80 61,759 14.61 7 1.49 0.113 0.10
Age over 80 25,152 5.95 3 0.64 0.119 0.10
Fifth SEG 415,848 888 2.135 1.83
Age 0 to 15 55,262 13.29 3 0.34 0.054 0.05
Age 16 to 25 33,447 8.04 10 1.13 0.299 0.26
Age 26 to 45 141,280 33.97 411 46.28 2.909 2.50
Age 46 to 65 104,328 25.09 439 49.44 4.208 3.61
Age 66 to 80 57,961 13.94 23 2.59 0.397 0.34
Age over 80 23,570 5.67 2 0.23 0.085 0.07
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conditions suffered by the patient explains health
utilization of any type and total health expenditures, as
usual in the risk adjustment literature [18], being most
of the significant differences produced by the different
use of hospital and specialist care. Hence, it is import-
ant to account for multimorbidity in order to under-
stand the different level of utilization of health services
by socioeconomic status, especially because patients
with multiple conditions are the most expensive ones
and therefore, those for whom health policy makersshould pay more attention to their mix of health ser-
vices provision.
Discussion
We find evidence of inequity in the use of health
services of different type in HIV patients by socioeco-
nomic status. While rich HIV patients use in average
more of hospital and specialist care, poor HIV patients
use in average more of primary care and spend more in
pharmaceutical products, other than the ART treatment,
common to all patients. With respect to demographic
Table 2 Descriptive cost per type of health service for HIV and non-HIV individuals
All Not-HIV patients HIV patients
Cost in different types of
health services
Mean
(std.dev.)
% Mean
(std.dev.)
% Mean
(std.dev.)
% of total expenditure
with ART
% of total expenditure
without ART
Primary Care (€) 261.14
(327.62)
23.05 % 261.00
(327.50)
23.33 % 378.19
(394.87)
2.85 % 6.80 %
Specialist Care (€) 257.08
(999.97)
22.69 % 255.82
(995.98)
22.87 % 1334.73
(2583.12)
10.07 % 23.99 %
Accidents and Emergency (€) 54.20
(142.78)
4.78 % 54.06
(142.01)
4.83 % 180.64
(438.16)
1.36 % 3.25 %
Hospitalizations (£) 376.29
(2294.01)
33.21 % 372.79
(2269.33)
33.32 % 3372.62
(9638.71)
25.43 % 60.62 %
Pharmaceutical Prescriptions
(€)
175.21
(513.43)
15.47 % 175.07
(513.11)
15.65 % 297.22
(726.50)
2.24 % 5.34 %
ART Treatment {€) 8.96 (262.51) 0.79 % 0.00 0.00 % 7697.00 (0.00) 58.05 % -
Total Cost (€) 1132.90
(3152.11)
100.00 % 1118.76
(3102.18)
100.00 % 13260.40
(11425.49)
100.00 % 100.00 %
N 2,262,698 2,260,063 2635
García-Goñi et al. International Journal for Equity in Health  (2015) 14:110 Page 6 of 10variables, HIV prevalence is greater for males and at
poorer socioeconomic groups. At the same time, we find
evidence of the ageing and “chronification” process of the
HIV population because there are patients older than 80
and most of them (76 %) suffer from other conditions.
Inequity in the access to health services and ART
has been extensively studied in low-income countries
and the evidence of its existence is a public concern.
The access to treatment is determinant to increase
quality of life and expectancy of life of HIV patients,
as well as for prevention and to allow patients to be
and feel part of the society and contribute to eco-
nomic activity [23]. Most high-income countries, dif-
ferently, present universal health systems where access
to ART for HIV patients and other health services
provision is guaranteed and many times, free at the
point of use. That is the case in the Basque Country, a
region in Spain responsible for health policy, planning,
and provision for its entire population. However, we
contribute to the literature finding that even when ac-
cess is guaranteed, there is still inequity in the use of
health services.Table 3 Average cost per type of health expenditure for HIV patien
First SEG N = 376 Second SEG
Cost in different types of health services Mean (std. Dev.) Mean (std. D
Primary Care (€) 357.01 (352.78) 373.69 (357.6
Specialist Care (€) 1656.69 (3134.08) 1266.92 (145
Accidents and Emergency (€) 178.23 (339.81) 179.46 (373.7
Hospitalizations (€) 4791.08 (13013.95) 2995.06 (831
Pharmaceutical Prescriptions (€) 280.06 (805.00) 251.11 (539.3
ART Treatment (€) 7697.00 (0.00) 7697.00 (0.00
Total Cost (€) 14960.07 (15519.86) 12763.24 (93Hence, the fact that universal health systems ensure
equal right to use health services for everyone, and that
all HIV patients obtain ART, do not mean that they have
achieved equity in the use of different types of health
services. Our analysis does not determine which is the
optimal mix of health services provision for HIV pa-
tients and it is not clear, with our data, whether there is
over-provision (under-provision) for the richest (poorest)
of specialist or hospital care. In fact, it cannot be directly
inferred that there exists discrimination. That question
is out of the scope in this paper. We add our result to
the literature on the inconclusive effect of health literacy
in HIV patients [24]. Our interpretation is that we might
have identified the existence of some barriers that pre-
vent poorest patients to demand equally those services
even when there is universal care with free provision at
the point of use. Although more research is needed to de-
termine the existence of those barriers, we point to lack of
information or a different educational level associated to
each socioeconomic group that might affect the way in
which they understand how to demand specialist or hos-
pital care, or the role of the GP as a gatekeeper. A betterts by socioeconomic group (SEG)
N = 399 Third SEG N = 501 Fourth SEG N = 471 Fifth SEG N = 888
ev.) Mean (std. Dev.) Mean (std. Dev.) Mean (std. Dev.)
8) 370.82 (371.14) 388.54 (407.68) 387.84 (432.31)
8.59) 1123.16 (1620.72) 1340.54 (1795.35) 1345.16 (3383.37)
6) 159.11 (294.87) 185.16 (364.54) 191.94 (582.04)
8.83) 2960.87 (9434.31) 3490.69 (10122.34) 3111.33 (8226.76)
4) 274.79 (648.04) 321.98 (779.25) 324.73 (775.82)
) 7697.00 (0.00) 7697.00 (0.00) 7697.00 (0.00)
37.31) 12585.76 (10870.28) 13423.91 (11495.67) 13058.00 (10412.49)
Fig. 1 Total health expenditures and prevalence ratio by
socioeconomic groups
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vices might lead richer population to demand a greater
amount of health services [25].
An important goal of universal health systems is to pro-
vide equity in the access to health services for a given level
of need. That involves not only access to the same ART but
also the same mix of specialist, hospital, A&E, primary care
or pharmaceutical treatments. In order to reach that aim, we
provide three recommendations. First, on the supply, to im-
prove and enforce clinical guidelines for health professionals
setting the type of health service provision appropriate for
different levels of health need. The objective would be to
reduce the discretional supply of health services and unjus-
tifiable variability. Second, on the demand, to provide infor-
mation and education programs to all HIV patients, and
more specifically to those in poorer socioeconomic status
about the appropriate demand of the different types of
health services (when to go to primary care, specialist care,
or the hospital) in order to promote the same level of use
of health services. Finally, on the health system, a less frag-
mented organization of attention will offer a seamlessFig. 2 Proportion of HIV patients with different number of comorbidities btransition among levels of care and improve the access of
the most deprived patients to costly health services.
Furthermore, we have also shown evidence on how the de-
mand of health services by HIV patients is affected by the
number of other chronic conditions they suffer and, conse-
quently, we recommend to walk towards an integrated care
model in which patients are considered as a whole, with all
chronic conditions at once, instead of taking care of their
multiple conditions (when that is the case) independently.
This is especially important given the process of ageing and
“chronification” of the HIV population. That model of inte-
grated care might benefit from our methodology to identify
especially problematic patients presenting a number of
chronic conditions, which are the most expensive ones.
Unfortunately, there are some limitations in our data.
First, HIV diagnosis is not complete and our data only
comprehends 2635 patients. It is consequence of the
historical psychological stigma of HIV patients that still
makes to decrease the rate of identification of patients
to about 53 % (2635 out of 5002 patients receiving
ART). However, after consultation with health profes-
sionals, there is no apparent bias in the lack of diagnosis
by socioeconomic or demographic groups. It is more a
matter of hospital personnel providing but not register-
ing ART for any patient. Besides, our results in preva-
lence are consistent with other studies related to the
same population [26]. Another limitation is that we
excluded from our analysis the utilization of psychiatric
hospitals, home and day care, transportation, prostheses,
and other equipment provided to patients at home for
lack of data. We suggest further research to overcome
these limitations.
Conclusions
Inequality in the access to ART is the most important
global concern for public health policy makers withy socioeconomic groups (SEG)
Table 4 OLS estimations for different types of health expenditures
Dependent variable. N=2365
Primary Care (€) Specialist Care (€) Accidents and
Emergency (€)
Hospital Care (€) Pharmaceutical
Prescriptions (€)
Total Health Expenditures (€)
Coef.
(std.dev.)
Coef.
(std.dev.)
Coef.
(std.dev.)
Coef.
(std.dev.)
Coef.
(std.dev.)
Coef.
(std.dev.)
Coef.
(std.dev.)
Coef.
(std.dev.)
Coef.
(std.dev.)
Coef.
(std.dev.)
Coef.
(std.dev.)
Coef.
(std.dev.)
age 0 to 15 519,37**
(98,10)
- 593,93
(645,69)
- 153,00
(109,43)
- 250,38
(2408,43)
- 48,91
(178,94)
- 9262,59**
(2854,04)
-
age 16 to 25 252,11**
(60,55)
−289,48**
(107,60)
1123,02**
(398,53)
538,55
(739,45)
214,93**
(67,54)
51,23
(124,10)
865,42
(1486,51)
633,19
(2668,21)
27,57
(110,44)
−55,53
(195,86)
10180,05**
(1761,55)
877,97
(3105,87)
age 26 to 45 345,29**
(11,64)
−258,76**
(92,33)
1283,64**
(76,66)
404,06
(634,53)
209,21**
(12,99)
−6,13
(106,49)
3132,94**
(285,95)
1499,04
(2289,64)
204,92**
(21,24)
6,77
(168,07)
12873,01**
(338,86)
1644,99
(2665,20)
age 46 to 65 396,01**
(10,63)
−238,70**
(92,31)
1417,34**
(70,01)
412,78
(634,41)
159,41**
(11,86)
−80,22
(106,47)
3709,61**
(261,13)
1412,49
(2289,21)
352,07**
(19,40)
100,84
(168,04)
13731,43**
(309,45)
1607,19
(2664,70)
age 66 to 80 576,20**
(45,92)
−135,01
(101,58)
959,89**
(302,29)
−402,81
(698,09)
136,23**
(51,23)
−170,66
(117,16)
3280,82**
(1127,54)
−883,57
(2518,96)
851,94**
(83,77)
462,57**
(184,90)
13502,08**
(1336,16)
−1129,48
(2932,15)
age over 80 584,91**
(138,74)
−115,25
(158,95)
543,45
(913,14)
−709,40
(1092,38)
19,12
(154,75)
−270,21
(183,34)
291,89
(3406,04)
−3089,37
(3941,69)
912,88**
(253,06)
557,52
(289,34)
10049,26**
(4036,22)
−3626,71
(4588,25)
First quintile SEG1 - 968,65**
(96,52)
- 2918,92**
(663,35)
- 559,58**
(111,33)
- 12967,66**
(2393,61)
- 931,60**
(175,70)
- 26043,42**
(2786,23)
Second quintile SEG2 - 979,53**
(96,13)
- 2506,46**
(660,64)
- 552,90**
(110,88)
- 11063,24**
(2383,83)
- 893,35**
(174,99)
- 23692,50**
(2774,85)
Third quintile SEG3 - 980,46**
(96,09)
- 2331,26**
(660,36)
- 528,22**
(110,83)
- 10917,74**
(2382,84)
- 928,36**
(174,91)
- 23383,04**
(2773,70)
Fourth quintile SEG4 - 1009,07**
(96,29)
- 2599,75**
(661,78)
- 562,92**
(111,07)
- 11736,13**
(2387,95)
- 996,83**
(175,29)
- 24601,71**
(2779,64)
Fifth quintile SEG5 - 990,29**
(95,60)
- 2530,81**
(656,99)
- 553,94**
(110,26)
- 10894,76**
(2370,69)
- 962,66**
(174,02)
- 23629,46**
(2759,55)
Suffering from 1 to 3
chronic conditions
- −465,86**
(25,34)
- −1979,07**
(174,20)
- −398,60**
(29,23)
- −11237,24**
(628,60)
- −890,57**
(46,14)
- −14971,34**
(731,71)
Suffering from 4 to 6
chronic conditions
- −280,49**
(26,61)
- −1362,34**
(183,47)
- −270,03**
(30,79)
- −8513,50**
(662,03)
- −602,03**
(48,59)
- −11028,40**
(770,62)
Suffering more than 7
chronic conditions
- - - - - - - - - - - -
R-squared 0.4860 0.5538 0.2125 0.2548 0.1486 0.2098 0.1117 0.2133 0.1701 0.2826 0.5755 0.6373
** Significance level 2 %
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and mostly free at the point of use, all HIV patients have
equal right to ART and other health services provision.
However, our analysis shows that they do not equally
use the different types of health services. We have found
evidence that HIV patients in the richest socioeconomic
groups utilize more specialist and hospital care than
poorer patients; and HIV patients in the poorest socio-
economic groups utilize more primary care and pharma-
ceutical products than richer patients. Hence, there
might be some barriers preventing all patients to equally
demand every type of health service. While we do not
state which is the optimal mix of types of health services
by health need, we understand that a universal health
system should search for equal provision to patients of
equal need no matter their socioeconomic status. We
have pointed the different mix in the demand to barriers
related to information and educational levels. Our rec-
ommendations are based on implementing accurate clin-
ical guidelines in the mix of health services provision by
need, determined by experts, so that the deviations to
the supply are reduced; to provide information and edu-
cational programs for all but specifically for poorer HIV
patients so that they understand better when and to
which health provider they should demand health
provision; and to walk towards an integrated care system
in which all conditions suffered by the patient are taken
into account at once. Those recommendations should
help policy makers in the search for equity not only in
the legal access to ART and other health services, but
also in their actual demand and provision by HIV pa-
tients only based on need.
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